Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing dyskinesias for at least three months

Outpatients who are on a stable anti-parkinsonian treatment regimen for at least four weeks

Exclusion Criteria:

Surgical treatment for PD

Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated)

Advanced, severe or unstable disease (other than PD) or evidence of dementia that may interfere with the study outcome evaluations

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01385592

United States: Food and Drug AdministrationCanada: Health CanadaGermany: Ministry of HealthFrance: Ministry of HealthItaly: Ministry of HealthHungary: National Institute of PharmacySpain: Ministry of Health